|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abmaxis Inc., of Santa Clara, Calif., and MaimoniDex RA Ltd., of Jerusalem, signed an agreement to jointly develop a therapeutic human monoclonal antibody for the treatment of rheumatoid arthritis and other inflammatory diseases. Based on its discovery of a disease-causing molecule found only in the joints of RA patients, MaimoniDex has developed a murine monoclonal antibody that has shown bioactivities both in vitro and in vivo. Abmaxis will humanize and optimize the murine antibody to develop a drug suitable for therapeutic use. MaimoniDex will pay Abmaxis an up-front technology license fee and Abmaxis also is entitled to receive future milestone payments and ...